Biogen to close Spinraza EAP from November

Following the announcement that Spinraza/nusinersen will not be funded on the NHS, Biogen the manufacturer announced late yesterday that they will be closing the Expanded Access Programme (EAP) as of 1st November. The EAP is a temporary compassionate use arrangement with the NHS, which has enabled access to Spinraza by 80 Type 1 babies in the UK, since being introduced, with Biogen covering the cost of the drug.

Biogen issued this community statement, which now paves the way for focus on a managed access agreement, between NICE, NHS England and Biogen.

We and the wider SMA community group will be working to expedite progress in these talks, with the hope that Spinraza is made available via a managed access agreement, as soon as possible.


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.